A New Class of Cancer Drug.
Kills Cancer Cells. Protects Normal Tissue.
Limits DNA Damage.
Supports Genomic Stability.
Keeping America Safe
Protecting Civilians, First Responders and Our Military
from Nuclear Accidents and Terrorism.
BIO 300 sensitizes cancerous tumors to radiation-induced killing, while protecting normal tissues from harm.
BIO 300 limits DNA damage and genomic mutation from low dose radiation during medical imaging procedures.
Humanetics Awarded Patent to Mitigate Erectile Dysfunction Associated with Prostate Cancer Radiotherapy
Humanetics Receives $597,000 Federal Grant to Continue Development of BIO 300 as a Medical Radiation Countermeasure
National Space Biology Research Institute to Fund Testing of BIO 300 to Protect Astronauts from Space Radiation
Humanetics Corporation Granted FDA Clearance To Proceed With Cancer Treatment Study
Humanetics Corportation Developing Compound That Could Protect Against Damage Caused by CT Scans and X-Rays
New Grant Enables Humanetics Corporation to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients
Humanetics Corporation Enters Into Cooperative Research and Developement Agreement with the U.S. Army Medical Research Institute of Chemical Defense